Refine Search
(1)
(6)
(10)
(10)

Immunology

More than 65% of pipeline drugs are in early stages of development. Tumor necrosis factor, B lymphocyte antigen CD20 and nuclear receptor ROR gamma are some of the major targets under research for immunological diseases.

Rheumatoid Arthritis - Pipeline Review, H1 2018

  • $2,500
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2018’, provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheu...

Heart Transplant Rejection - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Heart Transplant Rejection - Pipeline Review, H1 2018’, provides an overview of the Heart Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Liver Transplant Rejection - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Liver Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Liver Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Psoriasis - Pipeline Review, H2 2018

  • $2,500
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H2 2018’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with a...

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics un...

Bone Marrow Transplant Rejection - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics un...

Grass Pollen Allergy - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Grass Pollen Allergy - Pipeline Review, H2 2018’, provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gras...

Lung Transplant Rejection - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Lung Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Lung Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developmen...

Anaphylaxis - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Anaphylaxis - Pipeline Review, H2 2018’, provides an overview of the Anaphylaxis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete ...

Myasthenia Gravis - Pipeline Review, H1 2019

  • $2,000
  • February 2019
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myasthenia Gravis - Pipeline Review, H1 2019’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia...